Bupropion/zonisamide

Bupropion/zonisamide (former tentative brand name Empatic, Excalia) is an experimental combination of bupropion which was under development for the treatment of obesity.^[1][2][3] Bupropion is a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist, while zonisamide is an anticonvulsant acting as a sodium channel blocker, T-type calcium channel blocker, and weak carbonic anhydrase inhibitor.^[1] The combination was being developed by Orexigen Therapeutics and reached phase II clinical trials prior to discontinuation.^[1][4][5]

Bupropion/zonisamide

Combination of
Bupropion	Norepinephrine-dopamine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Zonisamide	Sulfonamide anticonvulsant
Legal status
Legal status	Investigational
Identifiers
CAS Number	944389-00-8
(verify)

See also

• Naltrexone/bupropion